Cardiolipin Antibody IgM Test

If you have ever had an unexplained blood clot, a stroke that did not fit the usual risk profile, or repeated pregnancy losses without a clear cause, the answer may lie in your immune system rather than your blood vessels or reproductive organs. Cardiolipin Antibody IgM (anticardiolipin immunoglobulin M) is one of several autoantibodies (antibodies that mistakenly attack your own body) your body can produce when the immune system loses its ability to distinguish self from threat, targeting a fat molecule called cardiolipin that sits on the surface of your platelets and blood vessel walls.

This test is most commonly ordered as part of the workup for antiphospholipid syndrome, often abbreviated APS (a condition where the immune system creates antibodies that promote abnormal blood clotting and pregnancy complications). But it can also tell you whether your immune system is quietly misbehaving in ways that standard blood tests, including routine clotting panels and cholesterol checks, would never reveal.

What This Antibody Actually Does

Cardiolipin is a type of phospholipid, a fat molecule that forms part of cell membranes throughout your body. Normally, your immune system ignores it. In APS and related autoimmune conditions, B cells (the immune cells that manufacture antibodies) begin producing antibodies against cardiolipin and similar phospholipids. When these antibodies bind to cardiolipin on platelet surfaces and the lining of blood vessels, they disrupt the normal balance between clotting and blood flow.

The antibody does not work alone. In most autoimmune cases, it latches onto cardiolipin with the help of a carrier protein called beta-2 glycoprotein I (a blood protein that normally binds phospholipids). This antibody-protein complex is what triggers the clotting cascade to fire when it should not. The result can be a blood clot in a vein or artery, or interference with normal placental blood flow during pregnancy.

IgM vs. IgG: Why the Isotype Matters

Cardiolipin antibodies come in different classes, called isotypes. The two most clinically relevant are IgG and IgM. A systematic review of 177 studies found that IgG anticardiolipin antibodies show stronger and more consistent links to blood clots than IgM antibodies. In a multicenter study of over 1,000 APS patients, isolated IgM positivity (meaning IgM was positive but IgG was negative) was uncommon in people with clot-related APS, appearing in only about 3.5% to 5.4% of thrombotic cases.

Where IgM stands out is in pregnancy. That same multicenter study found isolated IgM positivity in 5.7% to 12.3% of obstetric APS cases, and it was independently associated with pregnancy complications. If you are a woman with repeated miscarriages, stillbirths, or severe preeclampsia, an IgM result may carry more weight than it does in the context of clotting alone.

Blood Clot Risk

The connection between anticardiolipin antibodies and blood clots is well established, but the strength of the link depends heavily on which isotype is positive and at what level. In a study of 100 people with lupus (an autoimmune disease where APS is common), IgG anticardiolipin antibodies were associated with deep vein thrombosis and low platelet counts, while IgM antibodies were more closely linked to a type of anemia caused by immune destruction of red blood cells.

A separate study of over 1,500 people from multiple ethnic backgrounds found that any positive anticardiolipin antibody, whether IgG or IgM, was associated with roughly a four-fold higher risk of stroke. That association held after adjusting for other stroke risk factors and did not depend on the degree of positivity or the specific isotype.

The most dangerous pattern is "triple positivity," where three types of antiphospholipid antibodies are all present at once: anticardiolipin, anti-beta-2 glycoprotein I, and lupus anticoagulant (a clotting test that detects a different type of antiphospholipid antibody interference). Triple positivity carries the highest risk for both clots and pregnancy complications. A single positive IgM result, especially at a low level, carries far less certainty.

Pregnancy Complications

APS is one of the most treatable causes of recurrent pregnancy loss, which is why identifying it matters so much. In a cohort of over 3,000 pregnant women, even low levels of anticardiolipin antibodies were associated with more pregnancy complications, though this association was driven primarily by IgG, not IgM. A study of 64 lupus patients found that IgM anticardiolipin antibodies were associated with recurrent miscarriage, low platelet counts, and prolonged clotting times on lab tests.

If you have had two or more unexplained miscarriages before 10 weeks, or one or more late pregnancy losses, or severe preeclampsia requiring early delivery, testing for the full panel of antiphospholipid antibodies (including cardiolipin IgM) is part of the standard evaluation recommended by rheumatology and obstetric guidelines.

The Assay Problem: Why Lab Results Vary So Much

This is one of the most important things to understand about this test. Cardiolipin IgM has the poorest agreement between different laboratory platforms of any antiphospholipid antibody. In a quality assurance study involving 56 laboratories, the variation between labs for IgM exceeded 50% on most test samples. In more than half of the testing rounds, labs could not even agree on whether a sample was positive or negative.

This means the same blood sample sent to two different labs could produce a positive result at one and a negative result at the other. The problem is worst at low antibody levels, exactly where clinical decisions are most uncertain. Different labs also use different cutoff values to define "positive," so a result of 15 MPL units (the standard measurement unit for this test) might be called negative at one lab and low-positive at another.

The practical takeaway: never act on a single cardiolipin IgM result, especially a low-positive one. Always confirm with repeat testing, ideally at the same laboratory using the same method, and always interpret the result alongside the full APS antibody panel.

Reference Ranges

Because of the extreme variability between assay platforms, there are no universal reference ranges for cardiolipin IgM. Most labs report results in MPL units (IgM phospholipid units) and define their own cutoffs based on the manufacturer's kit. The 2023 ACR/EULAR (American College of Rheumatology / European Alliance of Associations for Rheumatology) classification criteria for APS use a tiered approach that weights moderate to high antibody levels more heavily than low positives.

A large study of over 1,100 healthy blood donors confirmed that the standard cutoff for IgM is appropriate, but recommended that low-positive results (just above the cutoff) be labeled "indeterminate" and retested rather than treated as definitive positives. In a population-based German cohort of over 6,000 adults, IgM anticardiolipin showed an age-dependent increase, meaning older adults are more likely to have low-level positivity without any disease. Your lab's specific reference range matters more than any published threshold, and comparing results within the same lab over time is the only reliable way to track changes.

When Results Can Be Misleading

The biggest source of false results is the test itself. Switching labs or assay platforms between tests can produce apparent changes in your antibody level that reflect nothing more than measurement differences. If you are tracking this marker over time, always use the same lab.

• Infections: Viral and bacterial infections, including COVID-19, can trigger temporary anticardiolipin antibody production. A meta-analysis found antiphospholipid antibodies in nearly half of hospitalized COVID-19 patients, but these were mostly transient and not associated with the clotting pattern seen in true APS. Any positive result during or shortly after an acute infection should be repeated at least 12 weeks later.
• Medications: If you are taking immunosuppressive medications (such as those used for lupus or other autoimmune diseases), let your provider know when discussing results, as some treatments can affect antibody levels over time.
• Age: Population data show that IgM anticardiolipin positivity increases with age in healthy adults, meaning a low-positive result in an older person is more likely to be clinically meaningless than the same result in a younger person.

Tracking Your Trend

A single cardiolipin IgM result is a snapshot, not a diagnosis. International guidelines require that antiphospholipid antibodies be positive on at least two separate occasions, approximately 12 weeks apart, before they count toward a diagnosis of APS. This is not bureaucratic caution. It reflects the reality that antibody levels fluctuate. In a longitudinal study of people with recent-onset lupus followed for up to eight years, antiphospholipid antibody levels moved around over time, with some patients converting from positive to negative and back.

If your first test is positive, get retested at 12 weeks using the same lab and method. If both are positive, you have persistent positivity, which is far more clinically meaningful than a single reading. If you are making lifestyle or treatment changes aimed at autoimmune health, retest every 6 to 12 months to see whether levels are shifting. A trend from high-positive toward negative is generally encouraging, while a trend in the opposite direction warrants closer clinical attention.

What to Do With an Abnormal Result

A positive cardiolipin IgM, especially if confirmed on repeat testing, should prompt a complete APS antibody workup if you have not had one. This means testing for cardiolipin IgG, anti-beta-2 glycoprotein I antibodies (both IgG and IgM), and lupus anticoagulant. The combination of results matters far more than any single number.

If your full panel shows triple positivity (all three antibody types positive), your clotting risk is substantially higher and you should be evaluated by a rheumatologist or hematologist. If only cardiolipin IgM is positive at a low level with everything else negative, the clinical significance is uncertain, and watchful monitoring with repeat testing is usually appropriate. For women with pregnancy complications and a positive result, referral to a maternal-fetal medicine specialist experienced in APS is the right next step, because treatment with low-dose aspirin and heparin during pregnancy can significantly improve outcomes.